HUP0401013A3 - Active substance combination for medicamentous therapy of nicotine dependency and pharmaceutical composition containing it - Google Patents

Active substance combination for medicamentous therapy of nicotine dependency and pharmaceutical composition containing it

Info

Publication number
HUP0401013A3
HUP0401013A3 HU0401013A HUP0401013A HUP0401013A3 HU P0401013 A3 HUP0401013 A3 HU P0401013A3 HU 0401013 A HU0401013 A HU 0401013A HU P0401013 A HUP0401013 A HU P0401013A HU P0401013 A3 HUP0401013 A3 HU P0401013A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition containing
active substance
substance combination
nicotine dependency
Prior art date
Application number
HU0401013A
Other languages
English (en)
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of HUP0401013A2 publication Critical patent/HUP0401013A2/hu
Publication of HUP0401013A3 publication Critical patent/HUP0401013A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HU0401013A 2001-07-12 2002-07-05 Active substance combination for medicamentous therapy of nicotine dependency and pharmaceutical composition containing it HUP0401013A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10134038A DE10134038A1 (de) 2001-07-12 2001-07-12 Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
PCT/EP2002/007477 WO2003007966A1 (de) 2001-07-12 2002-07-05 Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit

Publications (2)

Publication Number Publication Date
HUP0401013A2 HUP0401013A2 (hu) 2004-08-30
HUP0401013A3 true HUP0401013A3 (en) 2011-03-28

Family

ID=7691630

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401013A HUP0401013A3 (en) 2001-07-12 2002-07-05 Active substance combination for medicamentous therapy of nicotine dependency and pharmaceutical composition containing it

Country Status (28)

Country Link
US (1) US20040167145A1 (hu)
EP (1) EP1404341B1 (hu)
JP (1) JP2005502633A (hu)
KR (1) KR20040013143A (hu)
CN (1) CN1527712A (hu)
AR (1) AR034767A1 (hu)
AT (1) ATE340576T1 (hu)
AU (1) AU2002354856B2 (hu)
BR (1) BR0211323A (hu)
CA (1) CA2452432C (hu)
CZ (1) CZ301204B6 (hu)
DE (2) DE10134038A1 (hu)
DK (1) DK1404341T3 (hu)
EA (1) EA007628B1 (hu)
ES (1) ES2274064T3 (hu)
HK (1) HK1063159A1 (hu)
HU (1) HUP0401013A3 (hu)
IL (2) IL159789A0 (hu)
MX (1) MXPA04000344A (hu)
MY (1) MY131858A (hu)
NO (1) NO20040119L (hu)
NZ (1) NZ530512A (hu)
PL (1) PL367779A1 (hu)
PT (1) PT1404341E (hu)
SK (1) SK112004A3 (hu)
UA (1) UA79752C2 (hu)
WO (1) WO2003007966A1 (hu)
ZA (1) ZA200400305B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
DE102007058504A1 (de) * 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
DE3843239C1 (hu) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
CA2203183C (en) * 1994-10-21 2008-04-08 Laszlo Czollner Process for producing derivatives of 4a,5,9,10,11,12,-hexahydro-6h-benzofuro[3a,3,2-ef][2]benzazepine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
EP0828489A4 (en) * 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatment using naltrexone and related compounds
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5965567A (en) * 1997-07-15 1999-10-12 Albany Medical College Method for treating nicotine addiction
OA11740A (en) * 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
ES2222227T3 (es) * 1999-08-13 2005-02-01 Southern Research Institute Piridomorfinanos y su utilizacion.
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie

Also Published As

Publication number Publication date
EA007628B1 (ru) 2006-12-29
HK1063159A1 (en) 2004-12-17
BR0211323A (pt) 2004-11-30
WO2003007966A1 (de) 2003-01-30
CZ200419A3 (cs) 2004-05-12
CA2452432A1 (en) 2003-01-30
EA200400116A1 (ru) 2004-08-26
DK1404341T3 (da) 2007-02-05
EP1404341A1 (de) 2004-04-07
KR20040013143A (ko) 2004-02-11
NO20040119L (no) 2004-01-30
ES2274064T3 (es) 2007-05-16
IL159789A (en) 2008-07-08
SK112004A3 (en) 2004-06-08
ZA200400305B (en) 2004-05-24
EP1404341B1 (de) 2006-09-27
AU2002354856B2 (en) 2007-05-31
UA79752C2 (en) 2007-07-25
CA2452432C (en) 2009-09-01
IL159789A0 (en) 2004-06-20
MY131858A (en) 2007-09-28
CZ301204B6 (cs) 2009-12-09
DE50208267D1 (de) 2006-11-09
PL367779A1 (en) 2005-03-07
HUP0401013A2 (hu) 2004-08-30
ATE340576T1 (de) 2006-10-15
NZ530512A (en) 2007-09-28
CN1527712A (zh) 2004-09-08
DE10134038A1 (de) 2003-02-06
PT1404341E (pt) 2007-01-31
US20040167145A1 (en) 2004-08-26
MXPA04000344A (es) 2004-05-04
JP2005502633A (ja) 2005-01-27
AR034767A1 (es) 2004-03-17

Similar Documents

Publication Publication Date Title
AU8206401A (en) Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
PL342162A1 (en) Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0402661A3 (en) Formulation and dosage form for the controlled delivery of therapeutic agents
HK1225311A1 (zh) 透皮或透粘膜應用活性劑的用途和製劑
EP1165048A4 (en) COMPOSITIONS AND METHOD FOR IMPROVED ADMINISTRATION OF IONIZABLE HYDROPHOLE THERAPEUTIC SUBSTANCES
HUP0200819A3 (en) Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
HUP0302726A3 (en) Methods of administering pharmaceutical composition containing epothilone analogs for the treatment of cancer and of preparation the same
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
HUP0104379A3 (en) New crystalline form of omeprazole and medicament containing it
NO20003051D0 (no) Metode for administrering av AspB28-humant insulin
HUP0202862A3 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
HK1082677A1 (en) Androgen pharmaceutical composition and use for manufacture of medicament
AU1262501A (en) Compositions for transdermal and transmucosal administration of therapeutic agents
GB0119012D0 (en) Transdermal delivery of drugs
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HRP20020893A2 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
PL361518A1 (en) Application of substance and pharmaceutical composition
HUP0401484A3 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine and pharmaceutical compositions containing the combination
HUP0303755A2 (hu) Szalmeterol és flutikaszon-propionát kombináció alkalmazása és ezt tartalmazó gyógyszerkészítmény
HUP0401013A3 (en) Active substance combination for medicamentous therapy of nicotine dependency and pharmaceutical composition containing it
EP1642591A4 (en) MEDICINAL COMPOSITION CONTAINING NF-KAPPA B LURE FOR TREATMENT AND PREVENTION OF RESPIRATORY DISEASES AND METHOD USING THE SAME
AU2002354856A1 (en) Active substance combination for medicamentous therapy of nicotine dependency
HUP0302535A3 (en) Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases
IL155819A0 (en) Methods of treatment comprising administration of substance p

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished